Tatumine, a peptide from Bacillus brevis Vm4-572-403

Area of Science:

• Microbiology
• Biochemistry
• Pharmacology

Background:

• Bacillus brevis Vm4 is a known producer of bioactive compounds.
• Mutagenesis is a common technique to discover novel natural products.
• Understanding microbial metabolites is crucial for drug discovery.

Purpose of the Study:

• To isolate and characterize novel compounds from a mutant strain of Bacillus brevis.
• To investigate the biological activity of the produced compounds, specifically tatumine.
• To determine the stability and potential applications of tatumine.

Main Methods:

• Chemical mutagenesis of Bacillus brevis Vm4 using N-methyl-N'-nitro-N-nitroso guanidine.
• Cultivation of the mutant strain under specific conditions (defined medium, 40°C).
• Isolation and partial characterization of tatumine, including molecular weight determination and solubility tests.
• Cytotoxicity assays on cultured sarcoma cells and thermal stability tests.

Main Results:

• Isolation of mutant 572-403 from treated Bacillus brevis cultures.
• Production of tatumine and edeine B by the mutant strain.
• Tatumine characterized as a spermidine-containing compound (MW < 730 d), soluble in water and isopropanol.
• Tatumine exhibited selective cytotoxicity against sarcoma cells, with activity retained after heating at 60°C for 1 hour.

Conclusions:

• The Bacillus brevis mutant 572-403 produces tatumine, a novel cytotoxic agent.
• Tatumine displays selective cytotoxicity against sarcoma cells, suggesting therapeutic potential.
• The compound's stability indicates it could be a valuable lead for anticancer drug development.